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Abstract
Background: GWAS owe their popularity to the expectation that they will make a major impact on diagnosis,
prognosis and management of disease by uncovering genetics underlying clinical phenotypes. The dominant
paradigm in GWAS data analysis so far consists of extensive reliance on methods that emphasize contribution of
individual SNPs to statistical association with phenotypes. Multivariate methods, however, can extract more
information by considering associations of multiple SNPs simultaneously. Recent advances in other genomics
domains pinpoint multivariate causal graph-based inference as a promising principled analysis framework for high-
throughput data. Designed to discover biomarkers in the local causal pathway of the phenotype, these methods
lead to accurate and highly parsimonious multivariate predictive models. In this paper, we investigate the
applicability of causal graph-based method TIE* to analysis of GWAS data. To test the utility of TIE*, we focus on
anti-CCP positive rheumatoid arthritis (RA) GWAS datasets, where there is a general consensus in the community
about the major genetic determinants of the disease.
Results: Application of TIE* to the North American Rheumatoid Arthritis Cohort (NARAC) GWAS data results in six
SNPs, mostly from the MHC locus. Using these SNPs we develop two predictive models that can classify cases and
disease-free controls with an accuracy of 0.81 area under the ROC curve, as verified in independent testing data
from the same cohort. The predictive performance of these models generalizes reasonably well to Swedish
subjects from the closely related but not identical Epidemiological Investigation of Rheumatoid Arthritis (EIRA)
cohort with 0.71-0.78 area under the ROC curve. Moreover, the SNPs identified by the TIE* method render many
other previously known SNP associations conditionally independent of the phenotype.
Conclusions: Our experiments demonstrate that application of TIE* captures maximum amount of genetic information
about RA in the data and recapitulates the major consensus findings about the genetic factors of this disease. In addition,
TIE* yields reproducible markers and signatures of RA. This suggests that principled multivariate causal and predictive
framework for GWAS analysis empowers the community with a new tool for high-quality and more efficient discovery.
Reviewers: This article was reviewed by Prof. Anthony Almudevar, Dr. Eugene V. Koonin, and Prof. Marianthi Markatou.
Background
Genome-wide association studies (GWAS) are consid-
ered to be one of the primary tools for determining
genetic links to disease. GWAS have been abundant in
recent scientific research with more than 900 primary
large-scale studies performed in the last 5 years. Each of
these studies has genotyped at least 100,000 single
nucleotide polymorphisms (SNPs) in cohorts that often
exceed 1,000 subjects [1]. Overall, the reason for popu-
larity of GWAS is the expectation that they will lead to
discovery of SNPs implicated in disease and develop-
ment of predictive models that can facilitate diagnosis,
management, and treatment of disease.
Despite recent expansion of genome-wide association
studies, methodologies for statistical analysis of the result-
ing data are still lagging behind. The most dominant para-
digm for such analyses is focused on assessing
contribution of individual SNPs to statistical association or
risk of developing a phenotype [2-5]. Multivariate methods
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ing the individual SNP signals can help classify the pheno-
types, and thus uncover additional evidence for possible
genetic risk factors. Among multivariate techniques, Baye-
sian networks, kernel-based classifiers and multivariate
regression are making their way as candidate new meth-
odologies for the analysis of GWAS data [6-11].
Of particular relevance to the goals of GWAS are recent
multivariate causal graph-based methods that are compu-
tationally efficient and can scale well to the dimensionality
of GWAS data [12-14]. Unlike simple discovery of univari-
ate associations, these methods can discover biomarkers
(SNPs) in the local pathway of the phenotype (referred to
as “local causal biomarkers”, see Figure 1 for a graphical
representation) under reasonably broad assumptions
[12-14]. Local causal biomarkers constitute the Markov
boundary and yield the highest accuracy predictions of the
phenotype, while other biomarkers do not contribute addi-
tional predictive information beyond what is contained in
the local causal ones [12-15]. In addition, the set of local
causal biomarkers exhibits maximum parsimony, beyond
which predictive accuracy is compromised [12-14,16].
Causal graph-based methods have been previously
applied in a number of studies involving various high-
throughput assays (e.g., microarray and proteomics) and
phenotypes, yielding both highly accurate and parsimo-
nious predictive models of disease as well as biomarkers
implicated in disease mechanisms [12,14,17,18]. To the
best of our knowledge, causal graph-based methods have
not been previously applied to analysis of GWAS data.
In this paper we perform a case study for applicability of
causal graph-based framework to analysis of GWAS data.
We chose to apply the methodology to rheumatoid arthri-
tis, a common autoimmune disease with unknown etiology
[19,20], precisely because the genetics of this disease has
been thoroughly studied in the last 20 years and there is a
general consensus in the community about the major
genetic determinants of this disease. Recent findings illumi-
nated the importance of auto-antibodies to citrullinated
protein/peptide antigens (ACPA), which could be routinely
detected by ELISA using anti-cyclic citrullinated peptides
(anti-CCP) and are now included as a diagnostic criteria
for rheumatoid arthritis [21]. The anti-CCP positive sub-
group of rheumatoid arthritis represents specific well-stu-
died features regarding genetic and environmental risk
factors [22,23], differs in clinical features and responsive-
ness to the treatment and, possibly, is pathogenetically dis-
tinct from the other forms of rheumatoid arthritis [20]. We
focus our analysis specifically on the anti-CCP positive sub-
group of rheumatoid arthritis using data from North
American Rheumatoid Arthritis Cohort (NARAC) [3] and
Swedish Epidemiological Investigation of Rheumatoid
Arthritis (EIRA) cohort [22]. These data have been pub-
lished and thoroughly analyzed using a wide range of uni-
variate methods.
In the remainder of this paper, we describe the appli-
cation of a state-of-the-art causal graph-based algorithm
TIE* (which is an acronym for Target Information
Equivalency) to anti-CCP positive rheumatoid arthritis
GWAS data [12]. We cover all major steps of a typical
study, including examining the data for potential biases,
discovery of biomarkers, testing the robustness of the
identified biomarkers, building predictive models and
validating the results in independent data.
Results and Discussion
Patterns of missing data in NARAC cohort are not
random with respect to the phenotype
On our initial examination of NARAC GWAS data we
have noticed that, even after applying data completeness
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Figure 1 Graphical representation of the local pathway concept.
The local pathway of the phenotype (shown with the ash blue colour)
contains all its direct causes (C1,C 2,C 3), direct effects (E1,E 2,E 3), and
direct causes of the direct effects (CE1). This is exactly the Markov
boundary of the phenotype. Other variables (X1,X 2,X 3,X 4,X 5)d on o t
belong to the local pathway. This definition of a local pathway ties in a
theoretically rigorous manner causality with predictivity, since the
Markov boundary is the smallest set of variables that contains the
maximum predictive information about the phenotype that is
contained in the data. Alternative definitions of the local causal pathway
that exclude direct causes of the direct effects (the so-called “spouse
variables”,s u c ha sC E 1) are also useful and specialized algorithms exist to
infer them from data. In GWAS data, the two definitions coincide
because of lack of spouse variables in GWAS designs.
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Page 2 of 13filtering (see Methods and Materials), many SNPs still
contain a large number of missing genotype calls. As a
matter of quality assurance, we have decided to test
whether the patterns of missing genotype calls contain
relevant information for predicting the phenotype. To
d os o ,w em o d i f yt h ef i l t e r e dd a t a s e ts u c ht h a to n l y
information about presence or absence of each SNP
genotype call is retained. In other words, each missing
SNP call is encoded as “1” and all non-missing calls are
encoded as “0”. Following the cross-validation design of
our study (see Methods and Materials), we use the
training set of NARAC subjects to build a classification
model to predict the phenotype based on all 490,073
SNPs. The resulting predictive model achieves an extre-
mely high classification accuracy of 0.96 AUC in
NARAC testing data (95% confidence interval: [0.95;
0.98] AUC) when classifying rheumatoid arthritis cases
and controls.
This finding indicates that SNPs are not missing at
random and there must be a pattern that may or may
not be biologically meaningful. One plausible biological
explanation is that the somatic modifications such as
mutations and copy number variations are causing the
genotyping platform to call missing values. Another
plausible biological explanation of non-random missing
SNP calls can be attributed to alternative haplotypes
linked to the MHC locus. To provide evidence for this
hypothesis, we perform a hyper-geometric test for
enrichment of SNPs with missing genotype values signif-
icantly associated with rheumatoid arthritis in the MHC
locus. Out of all 338,774 SNPs that have missing values,
17,379 (5.1%) have missing values significantly asso-
ciated with rheumatoid arthritis according to G
2 test at
0.05 false discovery rate. However, out of all 945 SNPs
with missing values in the MHC locus, 81 (8.6%) have
missing values significantly associated with rheumatoid
arthritis. Therefore, enrichment of SNPs at the MHC
locus is statistically significant (p-value < 10
-5).
Technological explanations of the association of
missing SNP data patterns with the phenotype are pos-
sible as well (e.g., due to batch effects). Short of per-
forming additional assays to evaluate significance of
the non-random patterns of missing data, a legitimate
approach to deal with these potentially biasing and
misleading SNPs is to remove them from the analysis.
In general, such a conservative approach may poten-
tially eliminate some of the relevant SNPs from the
input data and reduce overall predictive accuracy.
However, an additional analysis conducted by taking
into consideration information from SNPs with missing
calls and discussed below, shows that removing such
SNPs does not compromise predictive accuracy in our
study. We therefore employ this conservative filtering
throughout the present work.
As few as five SNPs can accurately predict anti-CCP
positive rheumatoid arthritis
Application of the causal graph-based method TIE* to
the training set of NARAC subjects results in two five-
SNP information equivalent Markov boundaries of the
rheumatoid arthritis phenot y p i cr e s p o n s ev a r i a b l e
(denoting case and control status of the subjects). The
two Markov boundaries jointly contain a total of six
SNPs and have four SNPs in common (Table 1). SNP
rs9275374 that is included in the first Markov boundary
is substituted by SNP rs9275390 in the second Markov
boundary due to these two SNPs exhibiting complete
linkage disequilibrium (LD) in our dataset (R
2 =1 ,s e e
Table 2). We fit kernel ridge regression to both Markov
boundaries to produce predictive models (molecular sig-
natures) of anti-CCP positive rheumatoid arthritis. Each
of these predictive models achieves 0.81 AUC (95% con-
fidence interval: [0.78; 0.84] AUC) in the independent
testing set of NARAC cohort (Figure 2).
An additional analysis where SNPs with missing geno-
type values are retained in the data results in a Markov
boundary with 8 SNPs (Table S1 in [Additional File 1])
and exactly the same predictive accuracy in the NARAC
testing set (0.81 AUC). Therefore, predictive accuracy is
not affected by removing SNPs with missing genotype
calls.
Causal graph-based predictive modelling yields
reproducible genetic biomarkers of rheumatoid arthritis
Five of the six SNPs that participate in the causal graph-
based predictive models (rs660895, rs6910071, rs9275390,
rs3129871, and rs9275374) map to HLA-DR locus at chro-
mosome 6, which is a component of MHC II (major histo-
compatibility complex II). The alleles of this complex have
been found to confer a predisposing effect, a neutral effect,
or a protective effect in rheumatoid arthritis [24]. SNP
rs12523624 maps to chromosome 5 within the FGF1
(Fibroblast Growth Factor-1) gene is not known to be asso-
ciated with rheumatoid arthritis, however polymorphisms
of this gene have been linked with psoriatic arthritis [25].
A recent meta-analysis in 5,539 rheumatoid arthritis
cases and 20,169 controls over 6 cohorts [26] reveals
that at least four out of the six identified SNPs retain
their statistically significant univariate association with
the phenotype (Table 3). Data for SNP rs9275374 is not
present in the meta-analysis; thus we cannot assess its
statistical significance. However, this SNP is in complete
LD with SNP rs9275390 (Table 2) and is therefore likely
to reproduce its univariate association in subjects out-
side NARAC cohort. Only one of the six SNPs,
rs12523624, does not retain its univariate association in
the meta-analysis (p-value = 0.3335). This SNP is also
found to be statistically non-robust as detailed in the
next section.
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statistically robust
To assess statistical robustness of SNPs in the two Mar-
kov boundaries and of the associated predictive accura-
cies, we perform re-sampling analyses over 1000 different
random splits of NARAC data into non-overlapping
training and testing sets. Each training set is used for
SNP selection by TIE* and fitting of predictive models
with kernel ridge regression, while each testing set is only
used for the final assessment of predictive accuracy. Over
1000 splits of the data, predictive models achieve an aver-
age accuracy of 0.82 AUC, with standard deviation 0.01
AUC (Figure 3). This demonstrates robustness of predic-
tive accuracy of our models in the NARAC cohort. Simi-
larly, five out of six SNPs reported in Table 1 show a
high degree of statistical robustness and are selected in
>50% of the training sets. Notably, 3 SNPs (rs660895,
rs9275390, and rs9275374) are selected in all 1000 train-
ing sets. SNP rs12523624, which is not validated by the
meta-analysis, also does not achieve significant robust-
ness under re-sampling; it is selected in only the original
training set. Table S2 in [Additional File 1] provides the
list of all SNPs that are selected in at least 50 (5%) out of
1000 training sets in NARAC data.
Many of the previously reported SNPs are statistically
independent of the phenotype given SNPs discovered by
the causal graph-based approach
Several dozens of SNPs have known and previously veri-
fied association with rheumatoid arthritis. A recent
study by Stahl et al. [26] provides a list of 47 such SNPs
in Tables 2, 3, and 4 of their article. Out of these SNPs,
only 20 are assayed in NARAC cohort using Infinium
HumanHap550 platform. Out of the latter 20 SNPs,
only one (rs6910071) is found by the causal graph-based
method in our study. The remaining 19 SNPs are statis-
tically independent of the phenotype (according to G
2
test at significance level a = 5%) conditioned on 4 Mar-
kov boundary SNPs in the MHC locus (see Figure 4).
Therefore, these 19 SNPs do not carry for tested
NARAC cohort any predictive information about rheu-
matoid arthritis beyond that provided by 4 MHC SNPs
discovered by the causal graph-based approach. Note
that SNPs rs2476601 (PTPN22) and rs3761857 (TRAF1-
C5) are known to be strongly associated with rheuma-
toid arthritis from previous analyses. These SNPs
require at least 3 SNPs from TIE* to be rendered condi-
tionally independent of the phenotype.
Table 1 SNPs identified by the TIE* method in NARAC training set
dbSNP ID Markov
boundary
Chromosome* Minor allele frequency in NARAC
cases
Minor allele frequency in NARAC
controls
Gene
name
Number coordinate
rs660895 1,2 6 32,577,380 53% 19% -
rs6910071 1,2 6 32,231,452 51% 20% C6orf10
rs9275390 1 6 32,669,156 48% 25% -
rs3129871 1,2 6 32,406,342 17% 37% HLA-DRA
rs9275374 2 6 32,668,526 48% 25% -
rs12523624 1,2 5 142,020,508 53% 48% FGF1
These SNPs participate in the two Markov boundaries of the rheumatoid arthritis phenotypic response variable (denoting case and control status of the subjects).
* based on dbSNP and GRCh37 Homo sapiens Genome Build 37 version 1.
Table 2 Contingency tables for the two SNPs that are in
complete linkage disequilibrium
rs9275390
NARAC
cases
AA AG GG NARAC
controls
AA AG GG
rs9275374 AA 0 0 182 AA 006 6
AG 0 468 0 AG 0 453 0
GG 213 0 0 GG 662 0 0
0 0.2 0.4 0.6 0.8 1
0
0.2
0.4
0.6
0.8
1
False positive rate (1-specificity)
T
r
u
e
 
p
o
s
i
t
i
v
e
 
r
a
t
e
 
(
s
e
n
s
i
t
i
v
i
t
y
)
MB1 (AUC=0.81)
MB2 (AUC=0.81)
Figure 2 ROC curves for the two causal graph-based predictive
models applied to NARAC testing set. Model denoted with
“MB1” was fit using five SNPs from the first Markov boundary; model
denoted with “MB2” was fit using five SNPs from the second
Markov boundary.
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Swedish subjects in EIRA cohort
We validate the NARAC-based predictive models of
rheumatoid arthritis in independent data from EIRA
cohort. Due to substantial differences in the subject
recruitment protocols, we start by assessing the statistical
differences between cases and controls in the two cohorts
and possible implications for the model performance. We
assess such differences by building and applying two clas-
sifier models trained to predict the cohort from which
the subjects are derived (NARAC or EIRA) from SNP
genotype data: (1) for cases and (2) for controls. The clas-
sifier for controls results in 0.53 AUC (95% confidence
interval: [0.50; 0.55] AUC). Since the predictive accuracy
of a random classifier (0.50 AUC) falls within the esti-
mated confidence interval, we conclude that the controls
in NARAC and EIRA cohorts are statistically comparable.
However, the classifier for cases leads to 0.60 AUC (95%
confidence interval: [0.58; 0.63] AUC), indicating that
NARAC cases are statistically different from EIRA, how-
ever the magnitude of this difference is relatively small.
This empirical analysis shows that the differences
between NARAC controls and EIRA controls are smaller
than between NARAC cases and EIRA cases. Thus, we
do not anticipate perfect generalization of NARAC-based
models to EIRA cases.
To control for the differences between EIRA and
NARAC cohorts, we validate NARAC-based models in
three independent datasets consisting of: (i) EIRA con-
trols and NARAC testing set cases, (ii) EIRA cases and
NARAC testing set controls, and (iii) EIRA cases and
controls. We emphasize that in order to avoid biasing
predictive accuracy the above validation datasets do not
contain any subjects that are used for building NARAC-
based models.
A ss h o w ni nt h ep r e v i o u ss e c t i o n ,t w oe q u i v a l e n t
models (based on two Markov boundaries) developed in
NARAC training set achieve predictive accuracy 0.81
AUC (95% confidence interval: [0.78; 0.84] AUC) in
NARAC testing set. We further validate in EIRA data
the model based on the first Markov boundary only
(Table 1), since SNP rs9275374 is not genotyped in
EIRA cohort. Figure 5 provides ROC curves for valida-
tion of the corresponding model in EIRA datasets.
When this model is validated with EIRA controls and
NARAC testing set cases, the obtained predictive accu-
racy of 0.78 AUC falls inside the 95% confidence inter-
val for NARAC data only, which confirms the expected
generalization of the model. Next, when the model is
applied to EIRA cases and NARAC testing set controls,
the resulting AUC is 0.74, which is lower than perfor-
mance in NARAC data only. When the model is applied
to EIRA cases and controls, its performance is 0.71
AUC. This decrease in performance is most likely a
result of compounding of the differences in cases and
controls of the two cohorts that were quantified earlier
in this section.
Using EIRA data we can also explore whether SNP
rs12523624 (that does not belong to the MHC locus),
which has been found to be statistically non-robust in
NARAC and invalidated in the meta-analysis in several
cohorts, is predictively essential for the causal graph-
based model of rheumatoid arthritis. We build a modi-
fied model by removing SNP rs12523624 from the first
Markov boundary and fitting kernel ridge regression to
the remaining 4 SNPs in NARAC training data. Interest-
ingly, the resulting model yields slightly better predictive
accuracy than the original 5-SNP model (Figure 6).
However, the observed differences are not statistically
s i g n i f i c a n t .H e n c ew ec o n c l u d et h a tt h ee f f e c to fS N P
rs12523624 on predicting rheumatoid arthritis is small
and this SNP is likely to be a false positive marker.
However, we note that the results in Figure 6 may be
slightly overoptimistic because both statistical robust-
ness analysis and meta-analysis (that informed the
removal of SNP rs12523624) utilize subjects used for
validation of the model.
Table 3 Results of meta-analysis for 6 SNPs selected by
the TIE* method
dbSNP ID Meta-analysis
odds ratio
Odds ratio
95% confidence interval
P-value
rs660895 3.29 3.12 3.46 0
rs6910071 2.88 2.73 3.03 0
rs9275390 2.22 2.12 2.34 <10
-16
rs3129871 0.51 0.48 0.53 <10
-16
rs12523624 1.02 0.98 1.07 0.33346
SNP rs9275374 was not included in the meta-analysis because it was either
not measured in some cohorts or not could not be imputed.
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Figure 3 Area under the ROC curve (AUC) for the causal graph-
based predictive models developed in 1000 different random
splits of NARAC data into training and testing sets.
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favourably to previously reported predictive techniques
The comparison of our results with prior efforts is facili-
tated by the fact that the same NARAC GWAS dataset
has been previously used for predictive modelling of
rheumatoid arthritis in the 16
th Genetic Analysis
Workshop [27]. In the context of this workshop,
Arshadi et al. applied gradient-boosting machine metho-
dology to predict case-control status of subjects in
NARAC cohort [28]. As can be seen in Figure 2 of their
paper [28], predictive accuracy in the independent test
set in NARAC does not exceed 0.77-0.78 AUC, which is
RA
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Figure 4 Previously known SNP associations become statistically independent of the phenotype conditioned on 4 SNPs discovered by
TIE*. The phenotypic response variable is shown with black circle in the middle ("RA”) and SNPs are shown with white ovals. SNPs that have a
univariate association with the phenotype (according to G
2 test at significance level a = 5%) have a path to “RA”. SNPs that become statistically
independent of the phenotype given a subset of 4 SNPs found by TIE* (so-called “conditioning set”) are connected with “RA” by indirect paths
that go through SNPs in the corresponding conditioning set.
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Figure 5 ROC curves for validation of the causal graph-based
predictive model of rheumatoid arthritis (that was developed
in NARAC training set) in EIRA cohort.
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Figure 6 ROC curves for validation of the modified causal
graph-based predictive model of rheumatoid arthritis (without
SNP rs12523624) in EIRA cohort.
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Page 6 of 13slightly lower than the results of our causal graph-based
models (0.81 AUC). Notably, Arshadi et al. achieves pre-
dictive accuracy greater or equal to 0.77 AUC only for
models based on at least 5,000-10,000 SNPs which is
four orders of magnitude larger than the number of
SNPs in our causal graph-based models (with five SNPs
only). In addition, it is worth briefly mentioning the
results of Liang et al. [29] and Jeffries and Zheng [30]
who have also analyzed NARAC dataset for predictive
modelling but have used SNPs selected in the prior ana-
lyses of the same NARAC dataset. Such choice of SNPs
is expected to yield overoptimistic estimates of predic-
tive accuracy [31], and thus results of these papers
should be treated with great caution. Although possibly
biased, the previously reported results still correspond
to lower predictive accuracy than the causal graph-based
models: Liang et al. achieved a proportion of correct
classifications equal to 76% and Jeffries and Zheng
achieved 0.75 AUC. Finally, in contrast with our work,
the computational methods used in prior studies to
identify SNPs do not have a theoretical basis for causal
interpretation.
HLA shared-epitope (SE) status has been suggested for
predictive purposes; therefore, we also compare the
accuracy of the causal graph-based predictive models
(based on combination of five SNPs) to the predictive
performance of the SE status that is recorded for all
subjects in EIRA and NARAC cohorts independently of
S N Pd a t af r o mG W A S .S Es t a t u si se n c o d e da s1w h e n
one of the following alleles is present: DRB1*0101, 0102,
0104, 0105, 0401, 0404, 0405, 0408, 0409, and 1001; and
0 otherwise. When applied to NARAC data, the perfor-
mance of SE status is 76% sensitivity and 68% specificity.
The performance of the causal graph-based model is
very similar and not statistically different: it achieves
81% sensitivity at the same level of specificity and 70%
specificity at the same level of sensitivity. When applied
to EIRA data, the performance of SE status is 85% sensi-
tivity and 50% specificity. The performance of the causal
graph-based model is again very similar and not statisti-
cally different: it achieves 82% sensitivity at the same
level of specificity and 44% specificity at the same level
of sensitivity. Although our SNP-based model does not
achieve a significant improvement in predictive accuracy
over using the SE status at the corresponding levels of
sensitivity and specificity, the SNP-based model is more
informative and potentially more practical since it can
operate at any desired level of sensitivity or specificity,
unlike the binary SE status which is limited to a single
level of sensitivity and specificity.
Conclusions
Our study demonstrates the benefits of using causal
graph-based methods for the analysis of GWAS data in
anti-CCP positive rheumatoid arthritis. When applied to
NARAC cohort, the causal graph-based method TIE*
has discovered 6 SNPs (mostly from the MHC locus) in
the local causal pathway of the phenotype that can be
used to predict anti-CCP positive rheumatoid arthritis
with the accuracy of 0.81 AUC. The predictive perfor-
mance also generalizes reasonably well to the indepen-
dent data from EIRA cohort. Finally, the SNPs identified
by the TIE* method render all other previously known
SNP associations conditionally independent of the phe-
notype in NARAC cohort. These findings, corroborated
by comparison with the literature and expert knowledge
of rheumatoid arthritis, suggest that TIE* allows for
unravelling of the maximum amount of genetic informa-
tion about the disease that is available in the data in a
highly efficient and short discovery cycle.
Methods
Dataset description and pre-processing
NARAC dataset contains 863 cases (subjects with anti-
CCP positive rheumatoid arthritis) and 1,181 controls
(rheumatoid arthritis-free subjects), which are genotyped
on the Illumina Infinium HumanHap550 platform for
545,080 SNPs [3] using whole blood as a source for
genomics DNA. First, we apply pre-processing methods
identical to the ones used in the original report on these
data [3]. Specifically, we use the following SNP filtering
steps/criteria: (1) SNP call must be present in >95% of
subjects ("completeness filtering”); (2) minor allele fre-
quency must be above 1%; and (3) SNP must not violate
Hardy-Weinberg equilibrium at a =1 0
-5. The following
number of SNPs is filtered in each of these steps,
respectively: 18,718, 22,984 and 13,305, resulting in a
dataset with 490,073 SNPs.
EIRA dataset contains 1,146 cases (subjects with anti-
CCP positive rheumatoid arthritis) and 1,078 controls
(rheumatoid arthritis-free subjects), which are genotyped
on the Illumina Infinium HumanHap300 platform for
317,503 SNPs [3,32]. We have only selected the geno-
types for SNPs selected in NARAC training data for
validation purposes of the causal graph-based predictive
models.
It is worthwhile to mention differences between EIRA
and NARAC subjects. EIRA cases are incident rheuma-
toid arthritis cases (on average about 7 months after the
first symptom onset, and registered at first encounter
with a rheumatology specialist). They have been recruited
from a whole population in mid and south of Sweden.
Thus they are not biased by selection in referral systems
and by severity and effects of treatment, but correspond
to a rather representative sample of incident cases of
rheumatoid arthritis in Sweden. On the other hand,
NARAC cases have been obtained by referral from rheu-
matology clinics in various parts of the U.S., and are thus
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ment. EIRA controls have been randomly selected to
represent the population in the areas of case recruitment
and to match the cases by sex, age and area of residence.
On the other hand, NARAC controls have been recruited
from New York Cancer Project which possibly introduces
selection bias [33]. Thus we conjecture that the differ-
ences between NARAC controls and EIRA controls are
smaller than between NARAC cases and EIRA cases.
Cross-validation design and methods for estimating
accuracy of predictive models
To estimate accuracy of predictive models, we use hold-
out cross-validation [34]. This design controls for SNP
selection and predictive model bias and eliminates the
possibility of overfitting [31,35,36]. First, NARAC data is
split at random into non-overlapping training (with
~67% or 1366 subjects) and testing (with ~33% or 678
subjects) sets. The split retains the proportion of cases
and controls. Then the testing set is put aside, while
SNPs are selected in the training set and predictive
models utilizing these SNPs are also developed in the
training set. Finally, accuracy of the above predictive
models is assessed in the testing set. In addition, we per-
form another validation of predictive accuracy using
subjects from EIRA cohort.
As a metric of predictive accuracy, we use area under
the ROC curve (AUC). This metric has larger statistical
power to detect predictive signal than the commonly
used proportion of misclassifications [37]. The ROC
curve is the plot of sensitivity versus one minus the spe-
cificity for a range of continuous or discrete classifica-
tion threshold values. AUC ranges from 0 to 1, with an
AUC equal to 0 indicating the classifier opposite to the
perfect, 0.5 representing a random (i.e., uninformative)
classifier, and 1 representing perfect classification [38].
The 95% confidence intervals on AUC are obtained
using the method by Delong et al. [39].
Causal graph-based methods for selection of SNPs
We apply the TIE* method to the training data of
NARAC for selection of SNPs that can be implicated in
the development of rheumatoid arthritis. The method
was introduced in [12] (a brief description of TIE* is also
given in [Additional File 2]) to enable probabilistic mod-
elling of multiple signatures of the disease. The method
is based on Markov boundary induction, which formally
connects biomarkers and the phenotype into a causal
graph ("pathway”) of the data generating process even
when this pathway is not known a priori [16,40-42]. TIE*
outputs all Markov boundaries of the phenotypic
response variable, which are minimal sets of SNPs that
render all other SNPs statistically independent of the
phenotype [40]. Since each of the Markov boundaries
corresponds to non-redundant biomarkers in a maxi-
mally predictive signature, TIE* addresses the phenom-
enon of multiplicity of molecular signatures and can
facilitate separation of statistical instability in biomarker
selection process from intrinsic information equivalency
in the biological system [12].
Under the following four standard and sufficient causal
discovery assumptions, Markov boundaries output by
TIE* contain only SNPs that belong to the local pathway
of the phenotype (i.e., all SNPs that are direct causes,
direct effects, and direct causes of the direct effects of the
phenotype, see Figure 1) or are statistically equivalent to
these SNPs [12-15]: (i) adjacency faithfulness relaxed to
allow for multiplicity of data-consistent local pathways
[43-45]; (ii) causal Markov condition; (iii) correctness of
statistical decisions, and (iv) causal sufficiency [14,15]. In
non-technical terms, the first two assumptions mean that
with the exception of empirical information equivalency
relations between SNPs, there is a direct correspondence
between data and directed acyclic data-generative graph
in terms of statistical relations. Specifically, there is an
edge between two SNPs if and only if they have non-zero
association in the data conditioned on every subset of
other SNPs. The third assumption means that determina-
tion of statistical (in)dependence relationships between
SNPs in the population from the available data sample is
correct. The fourth assumption means that every com-
mon cause of two or more measured SNPs is also mea-
sured in the dataset. We emphasize that these are only
sufficient assumptions, and modern Markov boundary
induction algorithms are robust to violations of the above
assumptions [13,14].
The extent to which these sufficient assumptions hold
or do not hold in GWAS data is currently unknown,
however we provide below some facts that allowed us to
conclude that these are reasonable assumptions for this
type of data. With regards to the first assumption
(relaxed faithfulness), prior research has established that
non-faithful discrete probability distributions are extre-
mely rare, and therefore it is reasonable to make this
assumption here [46]. The second assumption (causal
Markov condition) is a foundational assumption of Baye-
sian networks [47] and it is reasonable given empirical
success of Bayesian networks in modelling SNP-SNP and
SNP-phenotype relations, e.g. see [7,10,11,48]. The third
assumption (correctness of statistical decisions) can be
justified by the relatively large sample size in GWAS
dataset. Finally, the fourth assumption (causal sufficiency)
is reasonable because hundreds of thousands of SNPs are
measured in GWAS study that map to or are linked with
essentially all known genes in the human genome. On
the other hand, we admit that the possibility of hidden
confounders in GWAS data may challenge the causal suf-
ficiency assumption. Some possible sources of hidden
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employed genotyping platform to capture all genetic
variability (for example, some essential SNPs or rare var-
iants will never be in the dataset), unobserved mutation
and recombination processes causing linkage disequili-
brium, and SNPs with missing values that were removed
from the analysis. Nevertheless, under the first, second,
and third assumptions TIE* will not falsely remove true
direct causes of the phenotype from its output as long as
these SNPs are included in the input dataset. Thus, the
SNPs identified by TIE* can include direct causes of the
phenotype as well as distant causes or confounders in
high linkage disequilibrium with true direct causes.
We run TIE* using GLL (Generalized Local Learning)
as the base Markov boundary induction algorithm
[13,14]. This choice of the base algorithm is motivated
by both its empirical performance in biomedical high-
throughput data and its theoretical properties [13,14].
The main operating principle of the GLL algorithm is
elimination of SNPs that are irrelevant for the pheno-
type (i.e., do not belong to its local pathway) via tests of
statistical independence conditioned on various subsets
of the tentative local pathway set of SNPs [14]. GLL is
run with the G
2 test at significance level a =5 %a n d
with maximum conditioning set size parameter max-k =
3. We also require at least 5 samples per cell in the con-
tingency tables for the G
2 test. The upper bound on the
size of the conditioning set is justified by empirical per-
formance in a variety of data distributions [13,14], as
well as by sample size limitations in our data. Specifi-
cally, given (i) a sample size of 1366 subjects in the
training dataset, (ii) the requirement of 5 samples per
cell in contingency tables, (iii) a binary response vari-
able, and (iv) and typically ternary SNP variables, the
maximum size of a conditioning set used to establish
independence relationships between SNPs and the
response variable is ⌊log3(1366/(5·2·3))⌋ =# 3S N P s
(where “⌊.⌋” denotes the integer part).
The GLL algorithm has a strong built-in capacity to
control against false positives (i.e., it is very unlikely that
the algorithm will output SNPs that do not belong to
t h el o c a lp a t h w a yo ft h ep h e n o t y p e ) ,a sw eh a v ed i s -
cussed in depth in [13] and illustrated under a variety of
high-dimensional settings using a well-controlled experi-
mental design. The quality of statistical decisions for
exclusion of irrelevant SNPs from the output of GLL is
determined by the combined, or effective, significance
threshold, which decreases at most exponentially with
the number of statistical independence tests applied to
each irrelevant SNP. Therefore, the combined probabil-
ity of not eliminating irrelevant SNPs and thereby
admitting false positives into the output of GLL is
exceedingly small. On the other hand, the algorithm
preserves a high combined power of statistical decisions
and is therefore robust to falsely removing SNPs that
truly belong to the local pathway of the phenotype. This
in turn is achieved by (i) using correlated tests of statis-
tical independence due to overlapping conditioning sets,
(ii) fixing max-k parameter to a small constant (e.g., 3),
and (iii) requiring at least 5 samples per cell in the con-
tingency tables. The latter two parameters restrict the
number of conditional independence tests performed by
GLL and balance the number of false positives and false
negatives that may appear in the output of the
algorithm.
Predictive modelling methods
After selecting SNPs with TIE*, we apply kernel ridge
regression to build predictive models of rheumatoid
arthritis using the NARAC training data [49,50]. We
chose kernel ridge regression because it is one of the
state-of-the-art supervised machine learning methods
that is robust to high-dimensional data, can model
highly non-linear relations between genotype and phe-
notype, and employs regularization to avoid overfitting
[49,50]. In addition, the kernel ridge regression algo-
r i t h mr e q u i r e sv e r yl i t t l et i m ef o rt r a i n i n go ft h ec l a s s i -
fier model (on the order of a few seconds in NARAC
data), which allows to parameterize it efficiently by
cross-validation. Kernel ridge regression is applied with
the radial basis kernel function K(x, y)=e x p ( - g||x - y||
2). The choice of this kernel function was based on pre-
liminary cross-validation experiments that indicated its
higher classification performance in NARAC data. The
regression ridge l and kernel width parameter g are
determined by 10-fold cross-validation in the training
set of NARAC data [51-53]. The above parameters are
optimized over values of l Î {10
-10,1 0
-8 , ..., 1} and
values of γ ∈
s
n
× 10−2,
s
n
× 10−1,...,
s
n
× 102

,w h e r e
n denotes the number of SNPs participating in the
model.
Reviewers’ comments
Reviewer #1
Reviewer’s comments
The present paper investigates the applicability of the
causal graph-based method TIE* to the analysis of
GWAS data. The following comments must be
addressed in the revision of the paper.
1) Causal graph-based methods rely on certain
assumptions. The authors must discuss in the manu-
script these assumptions and present convincing evi-
dence that these assumptions are justified in the context
of their case-study. How are these assumptions justified
in the context of the paper?
2) Background section, in the 6th paragraph it is sta-
ted that “In the remainder of this paper, we describe the
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Page 9 of 13application of the state-of-the-art causal graph-based
algorithm TIE* to.....”. There are several issues that need
to be addressed here. A) The authors need to include a
succinct, yet informative, description of the TIE* algo-
rithm. Paper references is not sufficient, this is supposed
to be a self-contained piece of work. What are the
strengths and limitations of the algorithm? Why is it
appropriate to use it in this case study? And what are
the important points of its implementation? B) Abbre-
viations should never be used without first defining
those. What does TIE* stand for? All abbreviations must
be defined first, then, they can be used.
3) Section entitled “Identified SNPs and predictive
models are also statistically robust”,f i r s tp a r a g r a p h .A )
It is stated in the manuscript that 100 different random
splits of NARAC data are used and Figure 3 presents
the distribution of AUC; this distribution is markedly
skewed indicating that perhaps the number of splits is
too small. Can the authors offer a rule that can be used
to decide the number of splits in any given situation? It
appears to me that the selection of this number is inti-
mately related to the error of the classifier. A discussion
of this point is necessary. B) What are the sizes of the
training and test sets used? C) Kernel ridge regression
was used; however, no intuition was given as to why
this is appropriate. Also, what types of kernels were
used and why?
4) Section entitled “Causal graph-based methods for
selection of SNPs”, first paragraph. It is stated that
“Under fairly broad assumptions, Markov boundaries
contain.....”. A discussion that justifies these assumptions
in this context must be presented. In the second para-
graph it is stated that the maximum conditioning set
parameter was 3. Why was this number selected?
Discuss.
5) TABLES: In Table 3 results for 6 SNPs are pre-
sented. Among the different p-values reported there are
p-values with ridiculous exponents, i.e. ten to the power
-216 or -158. This does not make any scientific sense!
What is the difference between these p-values and the
ones equal to 0? This merely reflects the accuracy of
the computer on which the analysis was carried out
and provides no information about the underlying
significance.
Authors’ response
The point-by-point response follows:
1) The revised manuscript provides a detailed descrip-
tion and justification of the assumptions of causal
graph-based methods used in this study. Please see sec-
ond and third paragraphs of the sub-section “Causal
graph-based methods for selection of SNPs”.
2. A) We added the description of the TIE* algorithm
to the Additional File 2 and also revised the algorithm
description in the manuscript, please see first paragraph
of the sub-section “Causal graph-based methods for
selection of SNPs”.
2. B) We explained all abbreviations in text when first
referenced.
3. A) The smoothness of the distribution is ultimately
dependent on the dataset sample size, classifier error,
number of splits, and possibly other factors. The nature
of this dependency is currently unknown and has not
been quantified in high-dimensional biomedical data,
such as GWAS. Therefore, per reviewer recommenda-
tion, we increased the number of splits to 1,000 that
leads to a more smooth empirical distribution. Please
see sub-section “Identified SNPs and predictive models
are also statistically robust” and Figure 3 in the revised
manuscript.
3. B) The sizes of the training and testing sets are now
stated in the updated sub-section “Cross-validation
design and methods for estimating accuracy of predic-
tive models.”
3. C) The justification for use of kernel ridge regres-
sion is provided in the revised manuscript, please see
sub-section “Predictive modelling methods”. This sub-
section further includes the rationale for using radial
basis function kernel which was used for our study.
4) Please see response to point 1) concerning causal
discovery assumptions. We set the maximum condition-
ing set size parameter max-k = 3 primarily because of
the sample size limitations as described in the fourth
paragraph of sub-section “Causal graph-based methods
for selection of SNPs” in the revised manuscript.
5) We agree with the reviewer, and corrected Table 4
accordingly.
Reviewer #2
Reviewer’s comments
The authors develop a SNP based biomarker for Rheu-
matoid Arthritis (RA) using data from the North Ameri-
can Rheumatoid Arthritis Cohort (NARAC) GWAS.
This is developed using a causal graph model TIE* (cita-
tion [10], Statnikov and Aliferis). The biomarker is
reported to have no worse predictability, using ROC
curves, than a number of other reported alternatives,
but with greater interpretability as a causal model (the
authors find a relatively small set of SNPs which appear
to account for all phenotype association). It is validated
with a separate data set, where its performance is found
to be approximately reproducible.
The methodology seems sound, with careful attention
paid to issues of data quality, and represents and inter-
esting case study in biomarker development. I have two
concerns:
1) The authors correctly point out that much analysis
of SNP association is confined to univariate analysis, but
this comment is perhaps most relevant to the clinical
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multivariate regression with second order interaction
terms. I believe the literature on multivariate methods
for SNP analysis is more extensive than the article sug-
gests, and I also believe that Bayesian networks have
been used in this application (eg Rodin SA, Boerwinkle
E (2005) Mining genetic epidemiology data with Baye-
sian networks I: Bayesian networks and example applica-
tion (plasma apoE levels) Bioinformatics 21(15): 3273-
3278.)
2) An important aspect of this study is the use of cau-
sal models, which are able to infer conditional indepen-
dence. This allows certain types of conclusions, for
example, that the phenotype may be independent of a
SNP conditionally on a specific SNP set G. This in turn
means that that SNP contains no information regarding
the phenotype not already contained in G. My under-
standing is that this is a consequence of the topology of
the graphical model, as illustrated by the authors. This
raises some concerns regarding goodness of fit. A causal
model is designed precisely to detect conditional inde-
pendence structure, expres s i b l eb yt h et o p o l o g y .M o s t
fitting algorithms have some control for overfitting (in
this case, usually expressed as spurious connectivity). It
is also possible, therefore, to infer spurious conditional
independence through excessive penalization of connec-
tivity, and an objective balance is very hard to achieve.
Is there any way, given the important of this issue in the
manuscript, to separately validate those reported find-
ings of conditional independence?
Minor corrections:
3) P5 L2 “an independent data <set>“
4) P11 A number of citations are not completely
formatted.
5) Perhaps more description of the TIE*method would
be helpful
Authors’ response
The point-by-point response follows:
1) The revised manuscript contains expanded litera-
ture review about usage of multivariate methods for pre-
dictive analysis of SNP data. This includes the citation
mentioned by the reviewer. Please see second paragraph
of the revised “Background” section.
2) The discussion of false positives and false negatives in
the output of the employed causal discovery algorithm is
provided in the last paragraph of sub-section “Causal
graph-based methods for selection of SNPs”. One can also
validate all found conditional independence relations in
independent data. In the case of our study, we were pro-
vided only with a small set of SNPs for the independent
validation dataset (EIRA), thus we cannot validate all con-
ditional independence relations found in the NARAC
dataset.
3) We corrected this issue in the revised manuscript.
4) We corrected citations and double-checked their
formatting.
5) We added the description of the TIE* algorithm to
the Additional File 2 and also revised the algorithm
description in the manuscript, please see first paragraph
of the sub-section “Causal graph-based methods for
selection of SNPs”.
Reviewer #3: Dr. Eugene V. Koonin
National Center for Biotechnology Information, NIH,
Bethesda, Maryland, United States
This reviewer provided no comments for publication.
Additional material
Additional file 1: Supplementary tables with SNPs selected by the
TIE* method.
Additional file 2: Description of the TIE* method.
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